Early CBCT shifts failed to predict dosimetric compromise in head and neck VMAT
Early three-dimensional CBCT shifts performed no better than chance for identifying patients with at least 3% PTV coverage loss.
Latest
IGF1R blockade overcame oHSV and radiotherapy resistance in glioblastoma and breast cancer models
Triple oHSV, radiotherapy and IGF1R blockade suppressed YAP1, produced tumour regressions and prolonged survival in glioblastoma and breast cancer models.
Five-fraction prostate radiotherapy showed low severe toxicity in men aged 75 or older
Five-fraction prostate radiotherapy achieved 82% three-year biochemical control with very few grade 3 toxicities in men aged 75 or older.
SBRT did not reproduce brachytherapy dose escalation in gynecologic cancers
SBRT provided competitive peripheral coverage in some plans but could not consistently reproduce brachytherapy’s central dose escalation after realistic margins were applied.
Prostate SABR practice varied despite broad adoption across Australia and New Zealand
Most surveyed oncologists offered prostate SABR, but patient selection, target volumes, focal boosts and access to supporting technology varied.
Hydrogel spacers reduced invasive treatment for radiation proctitis after prostate radiotherapy
Hydrogel spacer placement was associated with a 74% lower risk of gastrointestinal endoscopic hemostasis after prostate radiotherapy.
ESTRO defines clinical standards for high-dose thoracic reirradiation in NSCLC
ESTRO recommends selective high-dose thoracic reirradiation with comprehensive staging, limited target volumes and formal cumulative dose assessment.
Knowledge-based breast VMAT achieved low heart doses and no grade 3 toxicity
A standardized knowledge-based VMAT workflow achieved high target coverage, low cardiopulmonary doses and no grade 3 acute toxicity in 484 patients.
Deep-learning dose prediction generalized across six head and neck radiotherapy centres
A model trained at one centre closely predicted doses in 560 head and neck plans from six external institutions.
Concurrent atezolizumab was linked to HSV-1 toxicity during adaptive head and neck radiotherapy
Radiation reached 60 Gy in 15 fractions with adjuvant atezolizumab, while concurrent dosing was followed by HSV-1 reactivation in three of five patients.
EQD2 remains essential but uncertain in modern cervical HDR brachytherapy
EQD2 should remain the reporting standard, but delivery time, dose gradients, biological assumptions and dose accumulation materially affect its interpretation.
Durvalumab with radiotherapy achieved 39% two-year PFS in cCRT-ineligible NSCLC
Concurrent and consolidative durvalumab with definitive radiotherapy produced 39% two-year progression-free survival in patients ineligible for concurrent chemoradiotherapy.
One RapidPlan model generated ocular stereotactic plans across three fractionation schedules
A single knowledge-based model generated comparable ocular plans for 25 Gy once, 42 Gy in three fractions and 50 Gy in five.
Three MRI radiotherapy guidelines were largely consistent but differed in scope
IPEM, AAPM and NCS recommendations largely aligned, with complementary guidance for MRI simulation, MR-only workflows and MR-Linac quality assurance.
Daily adaptation improved target coverage and rectal sparing in postoperative prostate radiotherapy
Daily adaptation increased prostate-bed coverage from 92.1% to 98.5% and reduced high-dose rectal exposure during hypofractionated salvage radiotherapy.